Xencor (NASDAQ:XNCR) Shares Up 6.3% - Should You Buy?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) shot up 6.3% during mid-day trading on Tuesday . The company traded as high as $9.98 and last traded at $10.15. 24,532 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 664,849 shares. The stock had previously closed at $9.55.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on XNCR. Wall Street Zen downgraded shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Wells Fargo & Company cut their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. William Blair began coverage on shares of Xencor in a report on Monday, April 21st. They issued an "outperform" rating for the company. Wedbush reiterated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. Finally, Barclays decreased their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.50.

Xencor Stock Down 2.3%

The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $677.55 million, a PE ratio of -2.98 and a beta of 0.87. The stock's fifty day simple moving average is $9.01 and its 200-day simple moving average is $15.41.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The business had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Xencor's revenue for the quarter was up 104.6% compared to the same quarter last year. During the same period last year, the company earned ($1.11) earnings per share. As a group, sell-side analysts forecast that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Activity

In related news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the transaction, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. This represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.76% of the company's stock.

Institutional Trading of Xencor

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after purchasing an additional 78,066 shares during the period. Yousif Capital Management LLC increased its holdings in Xencor by 10.2% in the 4th quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company's stock worth $482,000 after buying an additional 1,944 shares in the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of Xencor by 12.7% during the 4th quarter. State of Alaska Department of Revenue now owns 39,773 shares of the biopharmaceutical company's stock valued at $913,000 after buying an additional 4,487 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of Xencor by 13.0% during the 4th quarter. Louisiana State Employees Retirement System now owns 33,800 shares of the biopharmaceutical company's stock valued at $777,000 after purchasing an additional 3,900 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Xencor by 11.7% during the 4th quarter. Rhumbline Advisers now owns 170,000 shares of the biopharmaceutical company's stock valued at $3,907,000 after purchasing an additional 17,743 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.